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Abstract
Diseased myocardium from humans and experimental animal models shows heightened
expression and activity of a specific subtype of phospholipase C (PLC), the splice variant
PLCβ1b. Previous studies from our group showed that increasing PLCβ1b expression in
adult mouse hearts by viral transduction was sufficient to cause sustained contractile dys-
function of rapid onset, which was maintained indefinitely in the absence of other pathologi-
cal changes in the myocardium. We hypothesized that impaired contractility alone would be
sufficient to induce a compensatory transcriptional response. Unbiased, comprehensive
mRNA-sequencing was performed on 6 biological replicates of rAAV6-treated blank,
PLCβ1b and PLCβ1a (closely related but inactive splice variant) hearts 8 weeks after injec-
tion, when reduced contractility was manifest in PLCβ1b hearts without evidence of induced
hypertrophy. Expression of PLCβ1b resulted in expression changes in only 9 genes at
FDR<0.1 when compared with control and these genes appeared unrelated to contractility.
Importantly, PLCβ1a caused similar mild expression changes to PLCβ1b, despite a com-
plete lack of effect of this isoform on cardiac contractility. We conclude that contractile
depression caused by PLCβ1b activation is largely independent of changes in the transcrip-
tome, and thus that lowered contractility is not sufficient in itself to provoke measurable tran-
scriptomic alterations. In addition, our data stress the importance of a stringent control
group to filter out transcriptional changes unrelated to cardiac function.
Introduction
Heart failure, a condition wherein the pumping ability of the heart is severely compromised,
develops as the end result of many different cardiac diseases. The prevalence of heart failure
worldwide is increasing and it contributes substantially to the rising cost of health care. Despite
this, current treatment options are largely limited to amelioration of symptoms. The failing
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heart exhibits a number of characteristics that contribute to pump failure. Some of these
involve non-myocytes, especially fibroblasts that are instrumental in remodelling the heart [1]
but some changes occur within the myocytes themselves [2]. Myocytes from failing hearts
exhibit structural changes as well as alterations in intracellular signaling pathways and calcium
handling [3–5]. Importantly, the calcium content of the sarcoplasmic reticulum (SR) is low-
ered, partly due to heightened calcium leak into the cytosol mediated by ryanodine receptors
and partly due to reduced SR calcium uptake via the sarcoendoplasmic reticulum calcium
ATPase (SERCA) [2, 6]. Failing myocytes characteristically show lowered expression of the SR
calcium pump SERCA2a encoded by Atp2a2 [7] along with reduced phosphorylation of phos-
pholamban (PLN), which further depresses SERCA2a activity [8]. PLN is phosphorylated by
protein kinase A downstream of β-adrenergic receptor activation and also by calcium-calmod-
ulin regulated kinase II (CaMKIIδ) at a neighbouring site [9]. These PLN phosphorylations dis-
inhibit SERCA and enhance lusitropy; therefore the lowered β-receptor expression and activity
that characterize the failing myocardium likely contribute to SR calcium depletion [10].
In addition to these considerations, recent studies in our laboratory have identified another
factor that contributes to contractile depression in the failing hearts. Failed myocardium from
humans and experimental animals showed heightened expression and activity of phospholipase
Cβ1b (PLCβ1b) [11], one of the splice variants of PLCβ1 [12] that initiates signaling responses
downstream of Gq-coupled receptor activation [13]. Our studies showed that increasing PLCβ1b
expression in adult mouse hearts by viral transduction was sufficient to cause rapidly developing,
sustained contractile dysfunction [14], which lasted for several months in the absence of other
pathological changes in the myocardium [14] (time course depicted diagrammatically in Fig 1).
Further evidence pointing to the significance of the contribution of heightened PLCβ1b to
pathology was provided by a more recent study [15], which showed that inhibiting PLCβ1b selec-
tively prevented or reversed contractile dysfunction following pressure overload induced by
trans-aortic constriction. Along with the improved contractility, the PLCβ1b-specific inhibitory
mini-gene reduced hypertrophy and prevented premature death [15].
Chronically heightened PLCβ1b expression results in compensatory hypertrophy and some
fibrosis only after a prolonged period (36 weeks) [14]. In agreement with this, transcriptional
activation of several ‘classical’ marker genes associated with hypertrophy and fibrosis was
detected at 36 weeks, but not at earlier time points. In contrast to the signaling mechanisms
responsible for the development of hypertrophy, it is not known whether transcriptional events
can be initiated specifically by low contractility, either as causes or consequences of contractile
dysfunction. PLCβ1b-induced contractile dysfunction, prior to the onset of hypertrophy, pro-
vides the possibility of examining whether there are transcriptional responses associated with
chronically depressed contractility in the absence of other changes related to the progression to
heart failure. Importantly, transduction of the closely related splice variant PLCβ1a had no
effect on contractility [14], or on any other discernible response when expressed in mouse
hearts at similar levels to PLCβ1b [16] and thus PLCβ1a provides a stringent control for all
studies involving PLCβ1b.
The literature contains many examples of transcriptome studies undertaken using hypertro-
phied or failed myocardium from humans and animal models [17–19]. Such studies have iden-
tified genes associated with cellular growth, fibrosis and remodelling as well as genes associated
with calcium handling. Many of these identified genes could contribute to contractile depres-
sion, singly or in combination, but such studies raise the issue of which transcriptional changes
are primarily causative and which are secondary to remodelling or to the loss of contractile
function. Contractile dysfunction caused by PLCβ1b does not induce other changes associated
with the progression to failure until a much later time point, and thus provides a unique oppor-
tunity to examine transcriptional changes associated directly with low contractile function.
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Such transcriptional changes could be either causative of dysfunction or secondary to the
chronically low contractility. With this in mind, we undertook a comprehensive mRNA-
sequencing study of mice with chronically low contractile function due to PLCβ1b overexpres-
sion, hypothesizing that reduced cardiac output alone would be sufficient to provoke at least a
partly compensatory transcriptional response. We used a time point early in the response to
avoid compensatory hypertrophy observed after several months of treatment [14] (Fig 1).
Methods
All experiments were conducted in accordance with the Australian Code of Practice for ‘The
Care and Use of Animals for Scientific Purposes’ of the National Health and Medical Research
Fig 1. Expression of PLCβ1b in mouse heart for 8 weeks causes contractile dysfunction. A. Comparative structures of PLCβ1b and PLCβ1a. PH is PH
domain, EF is EF hand domain, X and Y form the catalytic site, C2 is C2 domain, Gαq is the Gαq binding region.B.Western blots using anti-FLAG (Anti-
DYKDDDDK rabbit polyclonal antibody Abnova, 1/5000) and anti-β-tubulin antibody (1/1000 (abcam, ab6046)) showing FLAG-PLCβ1b and -PLCβ1a
expressions in left ventricle 8 weeks after rAAV6-mediated delivery, 3 samples per group.C. Time course of contractility changes measured as ejection
fraction (%) in hearts following treatment with rAAV6 expressing PLCβ1b, PLCβ1a or blank control. Values are ejection fraction (%), mean ± SEM, n = 6. *
p<0.01 relative to PLCβ1a or blank; data were analysed using a 2 way ANOVA for repeat measurements, as described previously (14). Red, PLCβ1b; blue,
PLCβ1a; black, blank control.D. Diagram showing the time frame of changes in function in relation to the 8 week time point used in the current study [14]. E.
Organ responses to PLCβ1b or PLCβ1a expression. Left panel: heart wt/tibia (mg/mm). Right panel; lung wt/tibia mg/mm. Values are mean ± SEM, n = 6.
doi:10.1371/journal.pone.0158317.g001
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Council of Australia and all studies were approved by the Alfred Medical Research and Educa-
tion Precinct Animal Ethics Committee (#1362/2013). Mice used were C57BL/6 obtained from
the Animal Resources Centre, Perth.
Expression of PLCΒ1b or PLCΒ1a in mouse hearts
rAAV6-PLCβ1b, rAAV6-PLCβ1a or rAAV6-blank (control virus with a promoter but no pro-
tein product [20]) were prepared as described previously [14]. Male mice, 8 weeks of age, were
injected with rAAV6-FLAG-PLCβ1b, rAAV6-FLAG-PLCβ1a or rAAV6-blank intravenously
(IV) via the tail vein at a vector dose of 3 x 1010 vg/g. This dose has been shown to produce
heightened expression of FLAG-PLCβ1b or FLAG-PLCβ1a in all chambers of the heart in all
animals [14]. Nine (9) weeks after viral delivery (8 weeks after PLCβ1b/PLCβ1a expression) the
animals underwent echocardiographic studies to evaluate contractile function, followed by
humane culling, removal of hearts and dissection of the left ventricle (LV) for RNA extraction
and western blotting. Extracted RNA subsequently was used for mRNA sequencing (mRNA--
Seq) analysis. Western blotting using anti-FLAG and anti-tubulin antibodies to confirm expres-
sion in all hearts used for sequencing was performed exactly as described previously (14).
Measurement of contractile function
In the current study, contractile function was assessed as ejection fraction determined by echocar-
diography. Anesthesia was maintained with 1.7% isoflurane. Echocardiography was performed
using a Philips iE33 ultrasound machine and a 15 MHz linear-transducer. After a short-axis 2-D
image of the LV at the level of the papillary muscles was obtained, 2-D guided M-mode images
were acquired digitally at a sweep speed of 133 mm/s. Ejection fraction [EF = (LVIDd3 –LVIDs3)/
LVIDd3, where LVIDd/s is the left ventricular internal diameter at systole ‘s’ or diastole ‘d’].
RNA-Seq methods for AAV6-PLCβ1a/b cardiac analysis
Total RNA from mouse heart left ventricle was prepared by Trizol extraction from flash-frozen
tissue. Six (6) biological replicates were used for each of rAAV6-blank, rAAV6-PLCβ1a and
rAAV6-PLCβ1b conditions. Ribosomal RNA depletion along with RNA fragmentation and
conversion to paired-end, strand-specific Illumina sequencing libraries were performed with
Illumina TruSeq preparation kits. Sequencing reads of 76 nt in length were obtained from mul-
tiplexed libraries on an Illumina NextSeq instrument at the Ramaciotti Centre for Genomics,
Sydney, Australia with (3.02 ± 0.11)  107 paired reads per heart (mean ± SEM). Reads were
aligned to the mouse transcriptome represented in the Illumina iGenomes mm10 UCSC release
using Tophat [21], achieving a read depth of (1.84 ± 0.07)  107 paired reads per heart
(mean ± SEM); this represents a mean alignment to the transcriptome of 61%. All mRNA-
sequencing reads and transcriptome-aligned read counts have been deposited in the NCBI
GEO with accession number GSE73909.
Statistical and informatic procedures
For ejection fraction measurements in Fig 1C, data were analyzed using a 2 way ANOVA for
repeat measurements, as described previously [14]. For the newly performed RNAseq measure-
ments in this study, the union mode of HTSeq [22] was used in a strand-specific manner to
quantitate reads pertaining to each mRNA. These data were used as input to the DESeq pack-
age which adjusted for library depth, performed differential expression calculations, and
derived false discovery rates (FDR). Similar findings were made when the HTSeq-quantitated
reads were used as input to edgeR for calculating differential expression [23]. For previous
Impaired Cardiac Function without Changed Transcription
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RNAseq studies [24–27] employing non-strand-specific mRNA reads, the union mode of
HTSeq [22] was used to re-analyze raw RNAseq reads, newly aligned to the mm10 UCSC
genome as above, without taking strand identity into account. DESeq was again employed for
differential expression calculations.
Comparison of PLCβ1a / PLCβ1b RNA-Seq data with existing RNA-Seq
data sets
Data sets for rAAV6-mediated adult cardiac expression of PLCβ1a and PLCβ1b were compared
with existing RNA-Seq datasets of αMHC/Myh6-driven expression of Gαq [24–26] or of full-
length PKCα cDNA in adult mouse hearts [27] commencing in the neonatal period. Although
PKCα expression was under the control of the doxycycline-suppressible tet-off Myh6 promoter,
doxycycline was never administered to dams or pups and thus transgene activity commenced at
birth, as for Gαq. Only mRNAs with a cardiac abundance of FPKM3 were included, in accor-
dance with the design of the original studies. In total, 781 individual mRNAs exhibited signifi-
cant difference between PLCβ1a/b and blank virus, between Gαq and wt controls (derived
specifically from [24]), or between PKCα and tet-off (tTA; TO) controls at a false discovery rate
(FDR)<0.1. The minimum fold-changes corresponding to these FDRs (up- or down-regulation)
were 1.16-fold (16%) for PLCβ1a/b vs blank virus, and 1.2-fold (20%) for Gαq vs wt or PKCα vs
tet-off. In order to compare expression changes for all 781 mRNAs across all three experiments,
the fold-change of each mRNA between ‘treatment’ and appropriate ‘control’ groups was com-
puted, the mean mRNA abundance value of control hearts was adjusted to 1 (log2 value = 0),
and the resulting variation across individual hearts from each group was displayed in a heatmap
(Partek Genomics Suite v6.6, Partek, St. Louis, MO).
Results
Functional and transcriptional responses to PLCβ1b or PLCβ1a
expression
PLCβ1b or the splice variant that is functionally inactive in heart, PLCβ1a, were overexpressed
in mouse hearts in vivo using rAAV6-mediated transduction (Fig 1A and 1B). Overexpression
of PLCβ1b in mouse hearts for 8 weeks resulted in depressed contractile function, expressed as
ejection fraction (EF%), without detectable hypertrophy. These data are similar to those
reported previously and are typical of 5 different cohorts (Fig 1C, 1D and 1E; Table 1) [14]. In
all cases, contractile dysfunction reached a plateau between 8–10 weeks after injection and was
sustained for several months followed eventually by hypertrophy. For convenience, data from
previous studies are depicted diagrammatically in Fig 1D, allowing the time frame of the cur-
rent study to be seen in relation to phenotype progression. We hypothesized that low contrac-
tility and decreased cardiac output would be sufficient to trigger a compensatory
transcriptional response. However, despite the low contractility in PLCβ1b-expressing mice,
unbiased whole-transcriptome analysis identified only minimal differences between hearts
from mice expressing PLCβ1b and hearts from mice transduced with a control vector that does
not express a protein product (rAAV6-blank). Only nine (9) genes showed significant expres-
sion differences between these two groups at a false discovery rate (FDR)< 0.1 (which repre-
sents a rather lenient filter compared to typical FDRs< 0.05 or< 0.02) (Fig 2, S1 Table).
Similar expression changes were observed when data from rAAV6-PLCβ1a expressing mice
were compared with rAAV6-blank mice. A total of 15 genes showed a transcriptional response
at FDR< 0.1 to either or both of PLCβ1b or PLCβ1a expression (Fig 2, S1 Table); these
changes were all of relatively low magnitude and did not include any canonical genes known to
be involved in the regulation of cardiac contractility or hypertrophy (Fig 3).
Impaired Cardiac Function without Changed Transcription
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Since mRNA-sequencing studies utilizing genetically- and/or surgically-manipulated mouse
hearts with similar numbers of biological replicates have typically observed hundreds of altered
mRNAs [24–26, 28, 29], we evaluated the variance to read-count relationship for the mRNAs
subjected to statistical comparison and found that variance declined for mRNAs with higher
read counts in the expected manner (S1 Fig). This suggests that the extremely modest tran-
scriptional response observed in rAAV6-PLCβ1a/b mouse hearts is not due to technical arte-
facts in the mRNA-sequencing procedure.
Comparison of PLCβ1b transcriptional responses to those resulting from
neonatal induction of upstream and downstream signal transducers
Cardiac overexpression of either Gαq (upstream regulator of PLCβ1b [16]) or of PKCα (acti-
vated downstream of PLCβ1b [14]) beginning in the immediate post-natal period are known
to induce widespread transcriptional responses, and in the case of Gαq a well-described pheno-
type of hypertrophy and dilation with severely blunted contractility occurs as a result [30–32].
As might be expected from the phenotypic outcomes, many more mRNAs are dysregulated in
adult hearts overexpressing Gαq than PKCα, in which transgene expression (under the control
of the αMHC /Myh6 promoter) began immediately after birth (see Methods) (Fig 4A) [24,
27]. We compared the transcriptomes of rAAV6-PLCβ1a and -PLCβ1b hearts (without filter-
ing for statistical significance of differentially-expressed mRNAs) to published mRNA-seq pro-
files of adult hearts overexpressing Gαq or PKCα from the post-natal period [24, 27].
However, neither PLCβ1a nor PLCβ1b hearts showed any evidence of Gαq- or PKCα-mediated
alterations in transcriptional profile (Fig 4B).
Discussion
Our previous studies showed that heightened expression of PLCβ1b is sufficient to cause
chronic contractile dysfunction, whereas expressing the closely related splice variant PLCβ1a
Table 1. Echocardiographic parameters in mice after 8 weeks of rAAV6 treatment.
blank PLCβ1a PLCβ1b
LVAWd (mm) 0.55 ± 0.03 0.53 ± 0.02 0.56 ± 0.03
LVAWs (mm) 0.97 ± 0.03 0.98 ± 0.02 0.92 ± 0.03
LVIDd (mm) 3.99 ± 0.20 3.92 ± 0.13 4.01 ± 0.08
LVIDs (mm) 2.30 ± 0.19 2.25 ± 0.11 2.67 ± 0.07*
LVPWd (mm) 0.74 ± 0.04 0.72 ± 0.02 0.72 ± 0.03
LVPWs (mm) 1.35 ± 0.05 1.30 ± 0.02 1.14 ± 0.05*
HR (bpm) 548 ± 15 551 ± 5 553 ± 7
EF (%) 80.9 ± 2.1 81.0 ± 1.2 70.2 ± 1.8*
PWT (%) 85.5 ± 8.9 80.3 ± 4.5 58.8 ± 4.1*
Heart weight (g) 31.8 ± 0.6 31.1 ± 0.5 31.3 ± 0.4
Mice were treated with rAAV6-FLAG-PLCβ1b, rAAV6-FLAG-PLCβ1a or rAAV6-blank for 8 weeks and contractile function was determined by
echocardiography. LVAW, left ventricular anterior wall thickness; LVID, left ventricular interior dimension; LVPW, left ventricular posterior wall thickness; HR,
heart rate; EF, ejection fraction; PWT, posterior wall thickening index. Subscript s and d represent left ventricular measurements at systole ‘s’ or diastole ‘d’.
Values shown are mean ± SEM, n = 6. Similar results were observed in 4 additional cohorts.
*p<0.05 relative to either blank or PLCβ1a control.
Statistical signiﬁcance between groups determined using one-way ANOVA (Tukey’s post-hoc test). Although similar data have been previously reported as
part of longer time course studies (14) data from the current cohort of mice are presented here for convenience in understanding the phenotype of these
mice 8 weeks after rAAV6 treatment.
doi:10.1371/journal.pone.0158317.t001
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had no discernible effect [14]. Furthermore, selectively inhibiting PLCβ1b activation pre-
vented/reversed heart failure following pressure overload [15]. Hearts expressing PLCβ1b
showed depressed contractile function without hypertrophy or fibrosis, at least until 36 weeks
after virus delivery. This provided an opportunity to examine whether transcriptional
responses occur in response to loss of contractility in isolation, without the difficulty of disen-
tangling these from responses associated with hypertrophied or failed myocardium. PLCβ1b
presented an especially attractive opportunity because PLCβ1a has no effect on contractility
and could thus serve as a stringent control.
Despite chronically lowered contractility, we detected only minor changes in gene transcrip-
tion associated with PLCβ1b expression and furthermore, similar changes followed expression of
PLCβ1a, even though PLCβ1a did not alter contractile function. Thus, depressed contractility per
se does not lead to widespread compensatory transcriptional changes. Our previous report noted
changes in canonical transcriptional markers of cardiac hypertrophy, once hypertrophy finally
ensued in PLCβ1b hearts, presumably as a result to prolonged contractile depression. After only
Fig 2. mRNAs regulated at FDR<0.1 by either or both of PLCβ1a or PLCβ1b expression. 15 mRNAs are displayed according to expression calculated
frommRNA-sequencing (FPKM). Red, PLCβ1b; blue, PLCβ1a; black, blank control. Values are mean ± SEM, n = 6. Blue lines with asterisk indicate false
discovery rate (FDR) <0.1 between PLCβ1a and blank (according to DESeq); red lines with asterisk indicate FDR <0.1 between PLCβ1b and blank. Full
gene descriptions and assignment to Gene Ontology categories are given in S1 Table.
doi:10.1371/journal.pone.0158317.g002
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8 weeks of chronically lowered contractility, we found no changes in the expressions of ANP and
α-skeletal actin, collagen-1A1, -3A1, α-or β-myosin heavy chain or phospholamban as measured
by RT-qPCR [14], nor did we in the current RNA-sequencing study. After 32 weeks of depressed
contractility, PLCβ1b-expressing hearts showed a modest degree of hypertrophy. At this time
point, increased expression of ANP and α-skeletal actin was observed in PLCβ1b-expressing
hearts compared with either PLCβ1a-expressing hearts or control hearts [14].
The finding that PLCβ1b-induced contractile dysfunction does not involve substantial tran-
scriptional changes is compatible with our previous data, which showed that the contractile
deficit could be fully reversed by treatment with a PKCα inhibitor for only 5 days [14, 33]. This
rapid reversal argues against an involvement of major transcriptional changes in the contractile
dysfunction. In addition, our studies in adult mouse ventricular myocytes and neonatal rat ven-
tricular myocytes showed that PLCβ1b overexpression results in dephosphorylation of phos-
pholamban and depletion of Ca2+ from the sarcoplasmic reticulum [14]. Neither of these
responses would be expected to require altered gene transcription, as they are likely dependent
on well-established phosphorylation cascades [34]. However, it is perhaps surprising that
chronically low contractility and reduced cardiac output does not of itself induce any substan-
tial transcriptional response to increase inotropy or lusitropy. Presumably the hypertrophy
that eventually ensues is such a response.
Fig 3. Canonical markers of cardiac hypertrophy in response to PLCβ1a or PLCβ1b expression.mRNAs are displayed according to expression
calculated frommRNA-sequencing (FPKM, fragments per kilobase of exon per million mapped fragments). Red, PLCβ1b; blue, PLCβ1a; black, blank
control. Values are mean ± SEM, n = 6. No comparisons to blank control were significant at FDR<0.1 (according to DESeq). Acta1, α-skeletal actin; Actc1, α-
cardiac actin; Atp2a2, SERCA2a; Myh6, α-myosin heavy chain; Myh7, β-myosin heavy chain; Nppa, atrial natriuretic peptide; Nppb, natriuretic peptide B;
Pln, phospholamban.
doi:10.1371/journal.pone.0158317.g003
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Fig 4. Comparison of rAAV6-PLCβ1-mediated gene expression changes to those caused by neonatal
overexpression of Gαq or PKCα. A. Venn diagram demonstrating limited overlap of 748 mRNAs regulated at FDR<0.1
in a comparison of Gαq transgenic mice vs WT [24] and 29 mRNAs regulated at FDR<0.1 in a comparison of PKCα
transgenic mice vs tet-off (TO) controls [27]. B. 761 unique mRNAs are displayed, from a composite of 15 mRNAs
regulated at FDR<0.1 in a comparison of PLCβ1a or PLCβ1b vs blank, 748 mRNAs regulated at FDR<0.1 in a comparison
of Gqα transgenic mice vs WT [24] and 29 mRNAs regulated at FDR<0.1 in a comparison of PKCα transgenic mice vs tet-
off (TO) controls [27]. Unsupervised hierarchical clustering of relative mRNA abundances (rows) and of individual hearts
(columns) was performed using Euclidean distance with average linkage. Colors represent log2 ratios for each individual
heart vs the mean of the appropriate controls (red is upregulated, blue is downregulated); the color range spans -2.0 to
+2.0 in log2 scale (from 4-fold downregulation to 4-fold upregulation in linear scale).
doi:10.1371/journal.pone.0158317.g004
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Whilst we conclude that chronically depressed contractility does not meaningfully alter
transcription, it must be considered that the PLCβ1b-expressing mice were unchallenged,
caged and fed and so had limited requirement for flight or fight responses. It remains possible
that the combination of chronically low contractility induced by PLCβ1b and a stressor requir-
ing increased cardiac performance might result in an altered transcription response compared
with stressed but otherwise untreated mice. As a result, stressing PLCβ1b-overexpressing mice
might result in a more rapid development of compensatory hypertrophy, together with its asso-
ciated transcriptional changes.
In cardiac signal transduction, PLCβ1b is immediately downstream of Gαq [16] and
upstream of PKCα [14]. Our previous data have provided evidence that PLCβ1b is specifically
activated downstream of Gαq in heart and thus similar transcriptional responses might be
expected. In neonatal rat ventricular myocytes, the phenotype caused by heightened expression
of Gαq is similar to that caused by PLCβ1b [16], with either of these causing primarily a hyper-
trophic response. However, both the phenotype and the transcriptional response to Gαq in
mouse hearts are dependent on the timing of Gαq overexpression. Use of the conventional
αMHC promoter system for Gαq transgene expression beginning immediately after birth pro-
motes hypertrophy, dilatation and failure [30–32] and this is associated with substantial
changes in the transcriptome [26]. In marked contrast, conditional overexpression of Gαq ini-
tiated in adult mouse hearts (a condition more similar to the rAAV6-mediated delivery used in
our studies) did not result in hypertrophy, dilatation or heart failure and the limited mRNA
expression data provided showed no changes in canonical markers of cardiac hypertrophy
[35]. Whilst comprehensive transcriptome data are unfortunately not available for this latter
condition, it seems unlikely that widespread transcriptional changes would be present in hearts
exhibiting normal function. As noted previously [14], functional responses of the mouse heart
to heightened PLCβ1b are similar to those reported previously in PKCα-overexpressing mice
[36] and our data are consistent with a signaling role for PLCβ1b upstream of PKCα in mouse
heart [14]. A relatively small set of mRNA expression changes was observed in PKCα-express-
ing hearts even though PKCα transgene expression commenced at birth [5, 27, 36]. Thus, find-
ings from transgenes expressed from the immediate post-natal period are not directly
comparable with the current data where heightened expression was initiated in adult animals.
This also speaks to the importance of evaluating phenotypes in which signaling has been
altered concomitant with the typical post-natal enlargement of the heart and acquisition of
adult metabolic and sarcomeric properties, in contrast to phenotypes in which signaling is only
altered once the heart has fully matured.
In addition to showing that depressed contractility per se does not initiate major transcrip-
tional responses, our study also stresses the importance of a stringent control group in studies
of this type. Although transcriptional changes were detected in response to PLCβ1b expression,
these do not appear intuitively connected to pathways known to cause, or to be affected as a
consequence, of blunted contractility. Because these alterations were similar to those in
PLCβ1a-expressing hearts, we were able to define these as events not specific to PLCβ1b over-
expression, but caused by the overexpression of the common molecular domains of PLCβ1a
and PLCβ1b, which are 97% homologous (Fig 1A) and differ only in membrane-targeting
capacity [37].
We have developed a mini-gene inhibitor that specifically targets PLCβ1b activation by pre-
venting its targeting to the sarcolemma and have shown that expressing this inhibitor in hearts
protects from heart failure following pressure overload. Additionally, we have identified the
binding interface responsible for sarcolemmal targeting, by showing that proline-rich
sequences in the extreme C-terminal sequence of PLCβ1b bind to the SH3 domain of the scaf-
folding protein Shank3 [37]. This binding interface provides a potential therapeutic target for
Impaired Cardiac Function without Changed Transcription
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the development of a new class of inotropic agent. The finding that PLCβ1b does not induce
transcriptional changes makes targeting its activation a more attractive proposition for drug
development.
Supporting Information
S1 Fig. Variance to read-count relationship for the mRNAs subjected to statistical compari-
son. Dispersion (variance) declines in accordance with increasing read depth-normalized
number of counts per mRNA.
(TIF)
S1 Table. Gene descriptions and assignment to Gene Ontology categories for the 15
mRNAs regulated at FDR<0.1 by rAAV6-PLCB1a or rAAV6-PLCB1b expression. Assign-
ment to Gene Ontology ‘biological process’ categories was performed using the Cytoscape
plugin BiNGO [1]. Chd6 (chromodomain helicase DNA binding protein 6) had no Gene
Ontology entry and is therefore not listed.
(XLS)
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